Notch信号通路在卵巢癌中的研究进展

doi:10.3969/j.issn.1004-616x.2023.06.012

癌变·畸变·突变 ›› 2023, Vol. 35 ›› Issue (6): 473-476.doi: 10.3969/j.issn.1004-616x.2023.06.012

Notch信号通路在卵巢癌中的研究进展

刘志彬, 岳文涛

首都医科大学附属北京妇产医院/北京妇幼保健院中心实验室, 北京 100026

收稿日期:2023-04-17 修回日期:2023-10-24 出版日期:2023-11-30 发布日期:2023-12-09
通讯作者: 岳文涛
作者简介:刘志彬，E-mail：liuzhibin@mail.ccmu.edu.cn。
基金资助:
国家自然科学基金(82002739)；首都卫生发展科研专项(首发2022-2-2116)；首都医科大学附属北京妇产医院北京妇幼保健院中青年学科骨干培养专项(FCYY202018)

Received:2023-04-17 Revised:2023-10-24 Online:2023-11-30 Published:2023-12-09

摘要/Abstract

摘要： 卵巢癌是致死率最高的妇科肿瘤之一，严重威胁女性健康。迄今为止，仍然缺乏精确的诊断和治疗靶点。Notch信号通路是在进化上高度保守的信号通路，且Notch信号传导需要细胞与细胞之间的接触，并引起Notch受体蛋白水解、加工以及随后胞内结构域与转录因子复合物的组装，继而引发级联信号传递，参与调控多种细胞过程，如增殖和分化。越来越多的研究证实Notch信号通路与卵巢癌发生密切相关。因此，本文主要概述经典Notch信号通路信号传导路径，以及Notch各信号分子在卵巢癌中的表达情况、分子作用机制、化学耐药性等，为完善Notch信号通路在卵巢癌中的相关研究细节，以及在卵巢癌患者中进行以Notch信号通路为靶向的诊断、治疗奠定基础。

关键词: Notch信号通路, 卵巢癌, 促癌机制, 靶向治疗

中图分类号:

R730.2

刘志彬, 岳文涛. Notch信号通路在卵巢癌中的研究进展[J]. 癌变·畸变·突变, 2023, 35(6): 473-476.

参考文献

[1] SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1):7-33.
[2] CHANDRA A, PIUS C, NABEEL M, et al. Ovarian cancer:current status and strategies for improving therapeutic outcomes[J]. Cancer Med, 2019, 8(16):7018-7031.
[3] XIA R L, XU M S, YANG J, et al. The role of Hedgehog and Notch signaling pathway in cancer[J]. Mol Biomed, 2022, 3(1):44.
[4] DEXTER J S. The analysis of a case of continuous variation in Drosophila by a study of its linkage relations[J]. Am Nat, 1914, 48(576):712-758.
[5] MORGAN T. The theory of the gene[J]. Am Nat, 1917, 51:513-544.
[6] KANZ D, KONANTZ M, ALGHISI E, et al. Endothelial-to-hematopoietic transition:notch-ing vessels into blood[J]. Ann N Y Acad Sci, 2016, 1370(1):97-108.
[7] HOPFER O, ZWAHLEN D, FEY M F, et al. The Notch pathway in ovarian carcinomas and adenomas[J]. Br J Cancer, 2005, 93(6):709-718.
[8] CHOI J H, PARK J T, DAVIDSON B, et al. Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion[J]. Cancer Res, 2008, 68(14):5716-5723.
[9] LIU Z Z, ZHU Y C, LI F F, et al. GATA1-regulated JAG1 promotes ovarian cancer progression by activating Notch signal pathway[J]. Protoplasma, 2020, 257(3):901-910.
[10] JIA D Y, UNDERWOOD J, XU Q P, et al. NOTCH2/NOTCH3/DLL3/MAML1/ADAM17 signaling network is associated with ovarian cancer[J]. Oncol Lett, 2019, 17(6):4914-4920.
[11] YANG J, XING H, LU D H, et al. Role of Jagged1/STAT3 signalling in platinum-resistant ovarian cancer[J]. J Cell Mol Med, 2019, 23(6):4005-4018.
[12] WANG M Y, WU L Y, WANG L, et al. Down-regulation of Notch1 by gamma-secretase inhibition contributes to cell growth inhibition and apoptosis in ovarian cancer cells A2780[J]. Biochem Biophys Res Commun, 2010, 393(1):144-149.
[13] DEFREITAS S, ROWE M, PACULIS L, et al. Integration of bioinformatics approaches and experimental validations to understand the role of Notch signaling in ovarian cancer[J]. J Vis Exp, 2020(155).doi:10.3791/60502.
[14] PARK J T, SHIH I M, WANG T L. Identification of Pbx1, a potential oncogene, as a Notch3 target gene in ovarian cancer[J]. Cancer Res, 2008, 68(21):8852-8860.
[15] KANG H, JEONG J Y, SONG J Y, et al. Notch3-specific inhibition using siRNA knockdown or GSI sensitizes paclitaxel-resistant ovarian cancer cells[J]. Mol Carcinog, 2016, 55(7):1196-1209.
[16] GAO M Q, CHOI Y P, KANG S, et al. CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells[J]. Oncogene, 2010, 29(18):2672-2680.
[17] WANG M Y, WANG J, WANG L, et al. Notch1 expression correlates with tumor differentiation status in ovarian carcinoma[J]. Med Oncol, 2010, 27(4):1329-1335.
[18] ALNIAIMI A N, DEMOREST-HAYES K, ALEXANDER V M, et al. Increased Notch1 expression is associated with poor overall survival in patients with ovarian cancer[J]. Int J Gynecol Cancer, 2015, 25(2):208-213.
[19] YANG M R, ZHANG G D, WANG Y Y, et al. Tumour-associated neutrophils orchestrate intratumoural IL-8-driven immune evasion through Jagged2 activation in ovarian cancer[J]. Br J Cancer, 2020, 123(9):1404-1416.
[20] KUHNERT F, CHEN G Y, COETZEE S, et al. Dll4 blockade in stromal cells mediates antitumor effects in preclinical models of ovarian cancer[J]. Cancer Res, 2015, 75(19):4086-4096.
[21] ZHOU J S, JAIN S, AZAD A K, et al. Notch and TGFβ form a positive regulatory loop and regulate EMT in epithelial ovarian cancer cells[J]. Cell Signal, 2016, 28(8):838-849.
[22] PARK J T, LI M, NAKAYAMA K, et al. Notch3 gene amplification in ovarian cancer[J]. Cancer Res, 2006, 66(12):6312-6318.
[23] MCAULIFFE S M, MORGAN S L, WYANT G A, et al. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy[J]. Proc Natl Acad Sci U S A, 2012, 109(43):E2939-E2948.
[24] ISLAM S S, ABOUSSEKHRA A. Sequential combination of cisplatin with eugenol targets ovarian cancer stem cells through the Notch-Hes1 signalling pathway[J]. J Exp Clin Cancer Res, 2019, 38(1):382.
[25] FENG Z Y, XU W D, ZHANG C G, et al. Inhibition of gamma-secretase in Notch1 signaling pathway as a novel treatment for ovarian cancer[J]. Oncotarget, 2017, 8(5):8215-8225.
[26] ALLAM H, JOHNSON B P, ZHANG M, et al. The glycosyltransferase GnT-III activates Notch signaling and drives stem cell expansion to promote the growth and invasion of ovarian cancer[J]. J Biol Chem, 2017, 292(39):16351-16359.
[27] KIM L K, PARK S A, YANG Y, et al. LncRNA SRA mediates cell migration, invasion, and progression of ovarian cancer via NOTCH signaling and epithelial-mesenchymal transition[J]. Biosci Rep, 2021, 41(9):BSR20210565.
[28] DRENZEK J G, SEILER N L, JASKULA-SZTUL R, et al. Xanthohumol decreases Notch1 expression and cell growth by cell cycle arrest and induction of apoptosis in epithelial ovarian cancer cell lines[J]. Gynecol Oncol, 2011, 122(2):396-401.

Notch信号通路在卵巢癌中的研究进展

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	覃熙媛, 朱莹, 李伟滔, 郑晓玲, 梁远秋. 上皮性卵巢癌组织中FoxM1的表达及其临床意义[J]. 癌变·畸变·突变, 2023, 35(4): 273-278.
[2]	崔潆, 肖汀, 郭会芹. 脂质代谢重编程对卵巢癌铂耐药影响的研究进展[J]. 癌变·畸变·突变, 2023, 35(4): 316-319.
[3]	谭健华, 赖姚圳, 唐丽华, 周莉. 2种不同疗法对晚期上皮性卵巢癌的疗效及患者预后影响因素分析[J]. 癌变·畸变·突变, 2023, 35(2): 131-138.
[4]	曹国栋, 曹芳. PI3K/AKT/mTOR信号通路及相关表观遗传调控机制在结直肠癌中的研究进展[J]. 癌变·畸变·突变, 2023, 35(2): 148-153.
[5]	马亚南, 吴楠, 金焰. 肿瘤微环境与卵巢癌化疗耐药机制的研究进展[J]. 癌变·畸变·突变, 2021, 33(5): 393-395,400.
[6]	黎梓蕊, 许键, 李红文, 张鹏. 口腔癌相关microRNA的研究进展[J]. 癌变·畸变·突变, 2020, 32(6): 481-484.
[7]	万树泉, 魏丽军, 王福花, 曾勇. miR-200b-3p和PAK2 mRNA在耐药卵巢癌组织中的表达及其临床意义[J]. 癌变·畸变·突变, 2019, 31(3): 216-221.
[8]	崔宏伟, 苏秀兰. 胃癌干细胞在胃癌靶向治疗中的研究进展[J]. 癌变·畸变·突变, 2018, 30(6): 490-493.
[9]	郭晓, 王蕊, 吴娟, 纪晓坤, 王珩, 张艳, 马阳, 杜芸. 肺腺癌患者新鲜细胞学标本EGFR基因突变检测及意义[J]. 癌变·畸变·突变, 2018, 30(1): 67-70.
[10]	杨丽, 张小茜, 张孟贤. Notch信号通路对胶质瘤干细胞作用机制的研究进展[J]. 癌变·畸变·突变, 2017, 29(4): 322-324.
[11]	谢琛静,刘向云,桂博,崇立明,许丽,潘琦,周莉,孙祖越. Ⅰ-单克隆抗体对人卵巢癌细胞株OC-3-VGH裸鼠皮下移植瘤的抑制作用[J]. 癌变·畸变·突变, 2013, 25(1): 13-17.
[12]	王琦, 田东萍, 李从铸, 钟卫祥, 丁文双. 人卵巢癌干细胞球的分离与悬浮培养方法[J]. 癌变·畸变·突变, 2010, 22(2): 141-145.
[13]	陈旻(综述), 李从铸(审校). B7-H4与卵巢癌早期诊断的相关研究进展[J]. 癌变·畸变·突变, 2009, 21(6): 479-481.
[14]	朱壮彦, 富晓敏, 穆雅琴, 李拴明, 赵富玺, 糜若然. 紫杉醇作用卵巢癌细胞系HO-8910后CYP1B1 mRNA及蛋白表达差异的研究[J]. 癌变·畸变·突变, 2009, 21(3): 214-217.
[15]	赵群（综述）/ 邓小虹（审校）. 蛋白质组学在卵巢癌诊治中的研究进展[J]. 癌变·畸变·突变, 2006, 18(3): 252-254.